Connect with us

Health

Mak Launches COVID Convalescent Plasma Investigational New Drug and Trial

Published

6 years ago

on

The Minister of Health-Hon. Dr. Jane Ruth Aceng (2nd Left) flanked by Prof. William Bazeyo-Chairperson Mak-RIF Grants Management Committee (Left), Project Principal Investigator-Dr. Bruce Kirenga (2nd Right), Dr. John Lusiba-UPDF (Right) and other officials from MLI, UBTS, JCRC launches the CCP Investigational New Drug and Trial on 16th September 2020, Main Hall, Makerere University, Kampala Uganda.
The Minister of Health-Hon. Dr. Jane Ruth Aceng (2nd Left) flanked by Prof. William Bazeyo-Chairperson Mak-RIF Grants Management Committee (Left), Project Principal Investigator-Dr. Bruce Kirenga (2nd Right), Dr. John Lusiba-UPDF (Right) and other officials from MLI, UBTS, JCRC launches the CCP Investigational New Drug and Trial on 16th September 2020, Main Hall, Makerere University, Kampala Uganda.

Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. First reported in early December 2019 in Wuhan China, it has since spread across all continents. Over 21 million cases have been reported, and more than 700,000 deaths have been recorded. The first case of COVID-19 in Uganda was reported on 21st March, 2020 and since then, more than 5,000 cases have been reported, with more than 60 deaths recorded.

There is no vaccine available for COVID-19, and treatments are only starting to emerge. There is emerging evidence to support use of COVID Convalescent Plasma (CCP) for treatment of COVID-19 especially among severe and critical patients. Plasma is the straw colored liquid portion of blood that remains after red blood cells, white blood cells, platelets and other cellular components of blood are removed.

Wednesday, September 16th 2020 was yet another day of great achievement to Makerere University in Kampala Uganda. On this day, Uganda’s Minister of Health; Hon. Dr. Jane Ruth Aceng officially launched the Uganda Coronavirus Convalescent Plasma Investigational New Drug and the CCP trial to assess the safety and efficacy of CCP in treatment of COVID 19 in Uganda. The launch was held at Makerere University’s Main Hall. Prof. William Bazeyo, the session chair and also Principal Investigator of the project gave welcome remarks on behalf of Makerere University’s Vice Chancellor. He thanked the government of the Republic of Uganda for funding this project and several others (now totaling to over 500 multidisciplinary projects) through Makerere University Research and Innovations Fund (MAK-RIF) https://rif.mak.ac.ug/ . He also thanked Hon. Dr. Aceng who graced the occasion as Chief Guest for the continued support from the Ministry. He ended by assuring the Hon. Minister that Makerere University Medical School is working hard to become number one in Africa after being ranked second for so long. He noted this was possible with more support from the Government of the Republic of Uganda.

L-R: Ag. Principal CHS-Prof. Kajja Isaac, Prof. William Bazeyo, UPDF Chief of Medical Services-Dr. Ambrose Musinguzi, UPDF Physician-Dr. John Lusiba, Dr. Bruce Kirenga (Right) and another official at the CCP Launch
L-R: Ag. Principal CHS-Prof. Kajja Isaac, Prof. William Bazeyo, UPDF Chief of Medical Services-Dr. Ambrose Musinguzi, UPDF Physician-Dr. John Lusiba, Dr. Bruce Kirenga (Right) and another official at the CCP Launch

Dr. Bruce Kirenga; the Director Makerere University Lung Institute http://mli.mak.ac.ug and also Principal Investigator of this project mentioned that despite evidence of possible efficacy of CCP in treatment of COVID-19, very few African countries have undertaken the collection and processing of CCP. He mentioned the aim of the project was to assess the feasibility of collecting, processing and storing of CCP for treatment of COVID-19 in Uganda. He emphasized the need to collaborate and collate all the related scientific facts throughout the collection, processing and storage of Convalescent Plasma.

The team approached COVID-19 recovered individuals who had been managed and discharged at the treatment centers across the country. To be included, participants needed to provide written informed consent, have documented evidence of SARS-CoV-2 infection by PCR, have documented evidence of full recovery from COVID-19, be at least 18 years old and meet all criteria for blood donation set by Uganda National Blood Transfusion Services in order to be eligible.

Dr. Bruce Kirenga said 87% of the 186 individuals who came to the center, qualified to donate. The donors were received from all regions of Uganda except Karamoja that had not registered an infection by commencement of the study. The median age of the donors was 33 years and 3.7% were females. A significant finding was that all the samples donated had enough antibodies to warrant use in treatment of COVID-19 patients.

The Minister of Health-Hon. Dr. Jane Ruth Aceng washes her hands after the launch on 16th September 2020 using the Touchless Handwashing Kit (TW-20) developed with support from the Government of Uganda through Mak-RIF
The Minister of Health-Hon. Dr. Jane Ruth Aceng washes her hands after the launch on 16th September 2020 using the Touchless Handwashing Kit (TW-20) developed with support from the Government of Uganda through Mak-RIF

In her address, Hon. Dr. Aceng thanked the scientists for the innovation and gave the green light to commence the CCP trial with immediate effect, now that the product was available. The Minister appealed to the general public to continue observing the COVID-19 Standard Operating Procedures as scientists continue to innovate, find treatment and cure for the deadly virus. She said the country had reached phase 4 of the pandemic and the virus was now killing on average 2-3 people a day. This she noted was indicative of widespread community transmission of COVID-19 meaning that the spread can no longer be controlled but can only be mitigated. She emphasized that COVID-19 in Uganda is real so anything proven that can be done to save life is highly welcome and appreciated.

The project was conducted by COVID Research (COVIDRES); a multi-disciplinary research group coordinated by the Makerere University Lung Institute (http://mli.mak.ac.ug). Other partners on the project are: Uganda People’s Defense Forces Medical Services, Mulago National Referral Hospital, Joint Clinical Research Center and Uganda Blood Transfusion Services. The team is now moving forward to undertaking the CCP trial.

Project details are shared and accessible here

Media Coverage of the COVID-19 Convalescent Plasma Investigational Drug launch

Broadcast Media

  1. NTV Uganda https://youtu.be/31DM3zeJqdM

Print Media

  1. The Independent https://www.independent.co.ug/makerere-scientists-big-move-on-covid-19-treatment/
  2. Makerere University Vice Chancellor’s Diary https://news.mak.ac.ug/2020/09/launching-covid-19-convalescent-plasma-drug/
  3. Uganda Update https://www.ugandaupdatenews.com/uganda-starts-plasma-based-treatment-trial-for-covid-19/
  4. The New Vision of September 17, 2020 page 3-See attached
  5. Daily Monitor of September 17, 2020 page 3-See attached

Pictures shared on https://we.tl/t-T99Kxua9nl

‘We Build for the Future’ ‘For God and My Country’

Compiled By: Musoki Walter Jack, 3rd Year Medicine and Surgery Student at Makerere University and

Harriet Adong, Communications Officer, Makerere University Research and Innovations Fund (Mak-RIF)

Mark Wamai

Related Topics:
Continue Reading

Health

Call for Applications: Masters Support in Self-Management Intervention for Reducing Epilepsy Burden

Published

5 days ago

on

May 25, 2026

By

An aerial photo of the College of Health Sciences (CHS), Makerere University showing Left to Right: The Sir Albert Cook Memorial Library, School of Biomedical Sciences, Davies Lecture Theatre, School of Public Health, Mulago Specialised Women and Neonatal Hospital (MSWNH)-Background Left and Nakasero Hill-Background Right, Kampala Uganda, East Africa.

The Makerere University College of Health Sciences and Case Western Reserve University, partnering with Mbarara University of Science and Technology, are implementing a five-year project titled “Self-management Intervention for Reducing Epilepsy Burden Among Adult Ugandans with Epilepsy.”

The program is funded by the National Institute of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS). One aspect of the program is to provide advanced degree training to qualified candidates interested in pursuing clinical and research careers in Epilepsy. We aim to grow epilepsy research capacity, including self-management approaches, in SSA.

The Project is soliciting applications for Master’s Research thesis support focusing on epilepsy-related research at Makerere University and Mbarara University, cohort 3, 2026/2027.

Selection criteria

  • Should be a Master’s student of the following courses: MMED in Internal Medicine, Paediatrics, Surgery and Neurosurgery, Psychiatry, Family Medicine, Public Health, Master of Health Services Research, MSc. Clinical Epidemiology and Biostatistics, Nursing, or a Master’s in the Basic Sciences (Physiology, Anatomy, Biochemistry, or any other related field).
  • Should have completed at least one year of their Master’s training in the courses listed above.
  • Demonstrated interest in Epilepsy and Neurological diseases, care and prevention, and commitment to develop and maintain a productive career, and devoted to Epilepsy, Clinical Practice, and Prevention.

Research Programs:

The following are the broad Epilepsy research priority areas (THEMES), and applicants are encouraged to develop research concepts in the areas of: Applicants are not limited to these themes; they can propose other areas.

  • The epidemiology of Epilepsy and associated risk factors.
  • Determining the factors affecting the quality of life, risk factors, and outcomes (mortality, morbidity) for Epilepsy, epilepsy genetics, and preventive measures among adults.
  • Epilepsy in childhood and its associated factors, preventative measures etc.
  • Epilepsy epidemiology and other Epilepsy related topics.
  • Epilepsy interventions and rehabilitation

In addition to a formal master’s program, trainees will receive training in bio-ethics, Good Clinical Practice, behavioral sciences research, data and statistical analysis, and research management.

The review criteria for applicants will be as follows:

·      Relevance to program objectives

  • Quality of research and research project approach
  • Feasibility of study
  • Mentors and mentoring plan; in your mentoring plan, please include who the mentors are, what training they will provide, and how often they propose to meet with the candidate.
  • Ethics and human subjects’ protection.

Application Process

Applicants should submit an application letter accompanied by a detailed curriculum vitae, two recommendation letters from Professional referees or mentors, and a 2-page concept or an approved full proposal describing your project and addressing Self-Management Intervention for Reducing Epilepsy Burden Among Adults or an epilepsy-related problem.

For more information, inquiries, and additional advice on developing concepts, don’t hesitate to get in touch with the following:

Makerere University College of Health Sciences

Prof. Mark Kaddumukasa:  kaddumark@yahoo.co.uk

Mbarara University

Ms. Josephine N Najjuma: najjumajosephine@yahoo.co.uk

Only short-listed candidates will be contacted for Interviews.

A soft copy should be submitted to the Administrator of the Epilepsy Project. Email: smireb2@gmail.com; Closing date for the Receipt of applications is 5th July 2026.

Mak Editor

Continue Reading

Health

ALLSTAR Training Program: Applications Open for AI and Machine Learning Course in TB Research

Published

1 week ago

on

May 20, 2026

By

Officials pose for a group photo with participants in the specialized short course on Artificial Intelligence (AI) and Machine Learning (ML) focused on their application in tuberculosis (TB) research, held from June 23–27, 2025, ResilientAfrica Network (RAN), Kololo MakSPH Annex. Makerere University School of Public Health, Kampala Uganda, East Africa.

Makerere University School of Public Health (MakSPH), through the Department of Epidemiology and Biostatistics, in collaboration with the Global Health Institute at the University of Georgia, USA, is inviting applications for an intensive five-day short course on the Foundations and Applications of Artificial Intelligence (AI) and Machine Learning (ML) in Tuberculosis (TB) Research.

Date: June 22–26, 2026
Time: 2:00 PM – 6:00 PM (EAT)
Venue: ResilientAfrica Network (RAN), Kololo MakSPH Annex

The course is designed for Master’s and PhD students, research fellows, junior researchers, and professionals in public health, medicine, digital health, TB/HIV, biostatistics, bioinformatics, computer science, geography, nursing, and related fields.

Participants will gain hands-on exposure to AI/ML applications in TB and TB/HIV research, including Generative AI, LLMs, Computer Vision, GeoAI, ethical AI use, data management, and model deployment.

Limited scholarships are available.
Application deadline: June 1, 2026

Read more and apply here: https://sph.mak.ac.ug/anouncement/allstar-training-program-applications-open-for-ai-and-machine-learning-course-in-tb-research/

John Okeya

Continue Reading

Health

MNCH e-Post Issue 132: Reimagining Africa’s Health Systems Takes Centre Stage at World Health Summit

Published

3 weeks ago

on

May 12, 2026

By

Prof. Peter Waiswa (C) with participants at the World Health Regional Summit on 29 April 2026 in Nairobi Kenya. Photo: MNCH. Makerere University Center of Excellence for Maternal, Newborn and Child Health (MNCH), based at the Makerere University School of Public Health in Kampala Uganda

Prof. Peter Waiswa was among key experts who featured at the World Health Regional Summit in Kenya. The high-level meeting ran under the theme Reimagining Africa’s Health Systems, bringing together researchers, policymakers, and health leaders to discuss how the continent can build resilient and equitable health systems in the face of climate and environmental shocks.

Prof. Waiswa participated in a panel discussion under the sub-theme Women, Adolescents, Child Health and Nutrition, which took place on Wednesday, 29 April 2026, from 09:30 to 11:00 EAT in Room CR3.

The session, chaired by Dr. Malachi Ochieng Arunda, focused on the growing intersection between environment, climate change, and health outcomes for mothers, adolescents, and children.

During the panel, Prof. Waiswa highlighted the urgent need to integrate climate adaptation into maternal and child health programming. He noted that rising temperatures, food insecurity, and extreme weather events are already disrupting health services and worsening nutrition outcomes across Africa. The discussion emphasized practical solutions, including strengthening primary healthcare, protecting vulnerable groups, and promoting cross-sector partnerships.

Click here to View the full MNCH e-Post Issue 132

Mak Editor

Continue Reading

Trending